Related Experiment Video

Updated: May 8, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

470

SGLT2 inhibitors for alleviating heart failure through non-hypoglycemic mechanisms

Ya-Ru Chen1, Fang-Yuan Zhu1, Rong Zhou1

  • 1Department of Cardiology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.

Frontiers in Cardiovascular Medicine
|December 24, 2024
PubMed

Insights

Sodium-glucose cotransporter-2 (SGLT2) inhibitors offer cardiovascular benefits for heart failure patients, even those without diabetes. These drugs work through non-sugar-lowering mechanisms to improve heart function and reduce adverse events.

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Sodium-glucose cotransporter-2 (SGLT2) inhibitors are established treatments for type 2 diabetes mellitus (T2DM).
  • Large clinical trials demonstrate significant cardiovascular benefits of SGLT2 inhibitors, including reduced cardiovascular events and heart failure hospitalizations.
  • These benefits extend to patients without T2DM, suggesting non-glycemic mechanisms of action.

Purpose of the Study:

  • To review the non-hypoglycemic mechanisms by which SGLT2 inhibitors prevent and alleviate heart failure.
  • To support the use of SGLT2 inhibitors for heart failure treatment in patients without T2DM.

Main Methods:

  • Review of evidence from major randomized clinical trials (EMPAREG-Outcomes, DECLARE-TIMI58, DAPA-HF).
  • Analysis of proposed non-glycemic pathways impacting cardiac function.
  • Synthesis of data on SGLT2 inhibitor efficacy in diabetic and non-diabetic heart failure populations.

Main Results:

  • SGLT2 inhibitors demonstrate efficacy in reducing cardiovascular events and heart failure hospitalizations.
  • Cardiovascular benefits are observed in both patients with and without T2DM.
  • Potential non-hypoglycemic mechanisms include reduced volume load, improved energy metabolism, ion homeostasis, reduced inflammation/oxidative stress, and direct cardiac effects.

Conclusions:

  • SGLT2 inhibitors offer significant cardiovascular protection through mechanisms beyond glucose lowering.
  • These drugs represent a promising therapeutic option for heart failure management, irrespective of diabetic status.
  • Further research into non-glycemic pathways can optimize SGLT2 inhibitor use in heart failure.

Keywords:
cardiovascular outcome trialsdapagliflozinempagliflozinheart failurenon-diabeticsodium-glucose cotransporter-2 inhibitor

More Related Videos

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

82
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.3K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
302
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
132
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
398
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
250
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
117
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
275